- Home
- MTDR vs AKRO Comparison
MTDR vs AKRO Comparison
Compare MTDR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTDR
- AKRO
- Stock Information
- Founded
- MTDR 2003
- AKRO 2017
- Country
- MTDR United States
- AKRO United States
- Employees
- MTDR N/A
- AKRO N/A
- Industry
- MTDR Oil & Gas Production
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MTDR Energy
- AKRO Health Care
- Exchange
- MTDR Nasdaq
- AKRO Nasdaq
- Market Cap
- MTDR 5.4B
- AKRO 4.5B
- IPO Year
- MTDR 2012
- AKRO 2019
- Fundamental
- Price
- MTDR $42.56
- AKRO $54.37
- Analyst Decision
- MTDR Buy
- AKRO Buy
- Analyst Count
- MTDR 15
- AKRO 10
- Target Price
- MTDR $62.79
- AKRO $73.56
- AVG Volume (30 Days)
- MTDR 1.7M
- AKRO 1.4M
- Earning Date
- MTDR 10-21-2025
- AKRO 11-07-2025
- Dividend Yield
- MTDR 3.60%
- AKRO N/A
- EPS Growth
- MTDR N/A
- AKRO N/A
- EPS
- MTDR 6.24
- AKRO N/A
- Revenue
- MTDR $3,556,751,000.00
- AKRO N/A
- Revenue This Year
- MTDR $14.61
- AKRO N/A
- Revenue Next Year
- MTDR $1.29
- AKRO N/A
- P/E Ratio
- MTDR $6.67
- AKRO N/A
- Revenue Growth
- MTDR 14.75
- AKRO N/A
- 52 Week Low
- MTDR $35.19
- AKRO $21.34
- 52 Week High
- MTDR $64.05
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- MTDR 57.74
- AKRO 67.61
- Support Level
- MTDR $39.93
- AKRO $54.22
- Resistance Level
- MTDR $42.31
- AKRO $54.41
- Average True Range (ATR)
- MTDR 1.37
- AKRO 0.14
- MACD
- MTDR 0.42
- AKRO -0.17
- Stochastic Oscillator
- MTDR 96.64
- AKRO 80.95
About MTDR Matador Resources Company
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.